Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506) discontinued the Phase III CO.23 trial of BBI608 plus best supportive care (BSC) to treat colorectal cancer after it failed an interim futility analysis of disease control rate (DCR). The company said no safety concerns were identified in the small molecule targeting cancer stem cells, but it did not disclose specific DCR data or futility criteria. The trial enrolled about 280 patients with advanced colorectal cancer who had failed all available therapies.
Dainippon said it will continue its other trials of BBI608 in combination regimens, including a Phase III trial to treat gastric cancer and a Phase II trial to treat colorectal cancer. The company gained BBI608 through its 2012 acquisition of Boston Biomedical Inc.
No comments:
Post a Comment